Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Shire news

30 Dec 2011 Share dealing by a Person Discharging Managerial Responsibility
15 Dec 2011 Shire plc Board and Committee Changes
14 Dec 2011 Director/PDMR Shareholding
12 Dec 2011 Director/PDMR Shareholding
08 Dec 2011 Shire Reports Positive Phase II Results for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII)
02 Dec 2011 ProAmatine® Update: Path Forward Agreed
01 Dec 2011 ADDERALL® (mixed salts of a single-entity amphetamine product) Supply Clarification
01 Dec 2011 Director/PDMR Shareholding
01 Dec 2011 Total Voting Rights
24 Nov 2011 Block listing six monthly return
22 Nov 2011 Shire Announces Regulatory Filings in US and EU for New Manufacturing Facility
21 Nov 2011 Director/PDMR Shareholding
18 Nov 2011 BRAVE Awards Recipients Announced
18 Nov 2011 Shire Announces Strategic Partnership for ADHD Medicines in Japan with Shionogi & Co., Ltd.
07 Nov 2011 Director/PDMR Shareholding
02 Nov 2011 PDMR Share Transactions
01 Nov 2011 Total Voting Rights
01 Nov 2011 Director Declaration
28 Oct 2011 Continued strong product sales performance in Q3: On track to deliver significant 2011 earnings growth
21 Oct 2011 EU study shows once-daily lisdexamfetamine dimesylate (LDX) effective for symptom control in children and adolescents with ADHD
20 Oct 2011 Bloomberg interview - Shire To Expand in Regenerative Medicine, CEO Says
13 Oct 2011 Shire Canada grants SickKids $200,000 to support paediatric research and ADHD
13 Oct 2011 Third quarter 2011 results date notification – October 28, 2011
03 Oct 2011 Total Voting Rights
30 Sep 2011 Director/PDMR Shareholding
26 Sep 2011 Director/PDMR Shareholding
22 Sep 2011 Shire Provides Update on ProAmatine® (midodrine HCl)
01 Sep 2011 Elections for Interim Dividend in Respect of the Six Months to June 30, 2011
01 Sep 2011 Total Voting Rights
25 Aug 2011 FDA Approves Shire’s FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
24 Aug 2011 Top-Line Results from Pivotal Trial of Dermagraft® for Venous Leg Ulcers
12 Aug 2011 Purchase of Shares by Employee Benefit Trust
11 Aug 2011 Half Yearly Report
03 Aug 2011 Director/PDMR Shareholding
02 Aug 2011 Director/PDMR Shareholding
01 Aug 2011 Director/PDMR Shareholding
01 Aug 2011 Total Voting Rights
29 Jul 2011 Notification of major interests in shares (26KB PDF)
28 Jul 2011 Shire's quarterly revenues grow by 25% to $1 billion for the first time
27 Jul 2011 Board Changes
18 Jul 2011 Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
15 Jul 2011 Second quarter 2011 results date notification – July 28, 2011
08 Jul 2011 Shire named “Business of the Year” at 2011 First Women Awards
07 Jul 2011 Shire files lawsuits against Watson and Roxane for infringement of VYVANSE® (lisdexamfetamine dimesylate) patents
01 Jul 2011 Shire files lawsuits against Sandoz and Amneal for infringement of VYVANSE®
01 Jul 2011 Total Voting Rights
28 Jun 2011 Shire completes acquisition of Advanced BioHealing, Inc.
27 Jun 2011 Shire named "Company of the Year" at Mediscience Awards for second consecutive year
24 Jun 2011 European Authorities Approve New Manufacturing Facility for Shire’s REPLAGAL® (agalsidase alfa)
24 Jun 2011 Purchase of Shares by Employee Benefit Trust
23 Jun 2011 FDA Advisory Committee Strongly Recommends Approval and Self-Administration of FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
21 Jun 2011 Shire Launches BRAVE Awards to Recognize Caregivers
21 Jun 2011 Director/PDMR Shareholding
21 Jun 2011 Shire Launches First BRAVE Awards to Recognise Carers
20 Jun 2011 Maroon 5 Lead Singer Adam Levine Raises Awareness of Attention-Deficit/Hyperactivity Disorder in Young Adults and Adults With "Own It"
17 Jun 2011 Director/PDMR Shareholding
14 Jun 2011 Shire Announces Judges Panel for New Scholarship Program for Students Diagnosed with ADHD
07 Jun 2011 Health Canada grants MEZAVANT® new expanded indication for maintenance of remission of Ulcerative Colitis
01 Jun 2011 Total Voting Rights
28 May 2011 First Results of European Survey Show Significant Impact Of ADHD At School And Home, Yet Parents Wait Over Two Years for An ADHD Diagnosis
25 May 2011 Calling All Students Diagnosed with ADHD – There’s a Scholarship for You!
25 May 2011 Shire Receives VYVANSE® Paragraph IV Notice Letters
24 May 2011 Block listing six monthly return
19 May 2011 Shire Receives VYVANSE® Paragraph IV Notice Letter
17 May 2011 Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc., including US marketed DERMAGRAFT®
12 May 2011 Bloomberg interview with Angus Russell, CEO
09 May 2011 Director/PDMR Shareholding
06 May 2011 Purchase of Shares by Employee Benefit Trust
04 May 2011 Director Declaration
03 May 2011 Total Voting Rights
28 Apr 2011 Shire delivers a strong first quarter performance
28 Apr 2011 Shire Reports Positive Results from Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) as Adjunctive Treatment in Predominant Negative Symptom Schizophrenia
26 Apr 2011 Results of the Annual General Meeting (20KB PDF)
21 Apr 2011 First quarter 2011 results date notification – April 28, 2011
19 Apr 2011 Notification of major interests in shares
06 Apr 2011 Shire files lawsuit against Watson Pharmaceuticals, Inc. for infringement of ADDERALL XR® patents and for breach of contract.
01 Apr 2011 Director/PDMR Shareholding
01 Apr 2011 Total Voting Rights
01 Apr 2011 Annual Information Update
29 Mar 2011 Notification of major interests in shares (45KB PDF)
24 Mar 2011 2010 Annual Report – DTR 6.3.5 Disclosure
21 Mar 2011 FDA Assigns PDUFA Date for Shire’s FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
21 Mar 2011 Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
03 Mar 2011 European Commission Approves Self-Administration Label for FIRAZYR® (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks
02 Mar 2011 Correction: Director/PDMR Shareholding
01 Mar 2011 Director/PDMR Shareholding
01 Mar 2011 Total Voting Rights
01 Mar 2011 Elections for Interim Dividend in Respect of the Six Months to December 31, 2010
28 Feb 2011 FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
28 Feb 2011 Shire Supports World Rare Disease Day 2011
28 Feb 2011 Shire Files Complete Response to FDA’s Not Approvable Letter for FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
24 Feb 2011 Shire Receives new Paragraph IV Notice Letter From Watson for ADDERALL XR®
10 Feb 2011 Outstanding 2010 results: Non GAAP EPS up 21% to $4.23. Good earnings growth expected in 2011.
08 Feb 2011 Shire Strengthens Specialty Pharmaceuticals Team with Senior R&D Appointments
02 Feb 2011 Santé Canada approuve Vyvanse® pour le traitement du TDAH chez les adolescents et les adultes
02 Feb 2011 Health Canada Approves Vyvanse® for the Treatment of ADHD in Adolescents and Adults
01 Feb 2011 Total voting Rights
31 Jan 2011 Full Year 2010 results date notification – February 10, 2011
27 Jan 2011 Shire Appoints New Head of European Government Relations and Public Policy
24 Jan 2011 Shire Recognized by ISPE Facility of the Year Awards Program
10 Jan 2011 Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules CII in Excessive Daytime Sleepiness Model
04 Jan 2011 Total Voting Rights

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?